Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
At Metabolic Medical Center in Mount Pleasant, Charleston, Murrells Inlet, Columbia, and Bluffton, South Carolina, Meridith Womick, MD, and the team are dedicated to providing their patients with all the tools they need to reach their healthy weight
Understanding one's genetic peptide pathway predispositions enables personalized predictions about blood pressure trajectory during semaglutide therapy
It helpsto lower lipid profile and in weight management program
Of these, semaglutide was evaluated in 15 trials (23 treatment arms
Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,687 followers
US$ 29.09
US$ 21.10
US$ 26.28
US$ 25.19
US$ 20.43
US$ 22.66
US$ 25.74
US$ 29.40
US$ 29.60
US$ 27.69
US$ 28.91
